Since they were discovered around three decades ago, molecular glues - also known as targeted protein degraders - have come a very long way as a therapeutic option for several different disease areas 🧬🔍 - from cancer to neurodegenerative disorders. 🧠 These small molecules - which ‘stick’ two proteins together 🧩 - are now seen as extremely promising solutions to potentially attack targets that were previously considered ‘undruggable’. As a result, there is also a rising number of molecular glue startups hoping to show clinical success with their candidates 🚀, with the targeted protein degradation market size poised to grow from $113.85 million in 2022, to $247.61 million by 2030. 📈 Check out our latest article to discover seven of the startups that are aiming to make it big in the field of molecular glues! 👇 https://lnkd.in/d2z3arfn C4 Therapeutics, Inc. | Degron Therapeutics | Magnet Biomedicine | Monte Rosa Therapeutics | Orionis Biosciences | Proxygen | TRIANA Biomedicines #Biotech #MolecularGlues #CancerResearch #ProteinDegradation #ProteinDegraders #BiotechStartups #NeurodegenerativeDisorders #BiotechIndustry
